#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Congenital leptin deficiency Retinitis pigmentosa Ocular lymphoma Epstein-Barr virus infection Neovascular age-related macular degeneration Juvenile chronic myelomonocytic leukaemia Immunoglobulin G4 related disease Paget's disease of the vulva Ventricular fibrillation Transient ischaemic attack Deafness neurosensory Fatty acid oxidation disorder Thrombocytopenia Asthma Uveitis More trials…

    Learn about Rare Diseases

    Cystic fibrosis – Diagnostics Haemophilia A without inhibitors – Trials in Disease Osteosarcoma – Treatment Lysosomal storage disorder – Trials in Disease Alternating hemiplegia of childhood Mucopolysaccharidosis – Basic Information Combined immunodeficiency – Basic Information Pelizaeus-Merzbacher disease – Diagnostics Niemann-Pick disease Advanced systemic mastocytosis – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    177Lu-Rhpsma-10.1 Lanifibranor Buparlisib POLYMYXIN B SULFATE L-Ascorbic Acid TUVATEXIB Dnth103 Ulotaront Bms-986340 Fosfomycin Trometamol Zalunfiban Anhydrous Cyclophosphamide Cefuroxime Axetil Soticlestat Arachis Hypogaea (762) Sepiapterin Tolvaptan Rifabutin DROSPIRENONE Bulevirtide More therapies…

    Learn about Your Condition

    Syphilis Anal incontinence Amnestic disorder Diabetes mellitus Hyperphagia Meningioma malignant Schizophreniform disorder Osteonecrosis of jaw Factor IX deficiency Juvenile idiopathic arthritis Encephalopathy neonatal Aphthous ulcer Haemolytic uraemic syndrome Premature baby Coronary artery bypass More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Pauls Stradins Clinical University Hospital

Pauls Stradins Clinical University Hospital

Pilsonu Iela 13, Riga, 1002, Latvia

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Darolutamide and Androgen Deprivation Therapy for Men with Metastatic Hormone-Sensitive Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • Darolutamide
    Latvia Lithuania Spain

  • Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Darolutamide
    Belgium Bulgaria Czechia Estonia Finland France +11

  • Study of Pembrolizumab with Chemoradiotherapy for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Mitomycin
    • Cisplatin
    • Fluorouracil
    Czechia Estonia France Hungary Italy Latvia +5

  • Study on the Effectiveness and Safety of PB016 and Vedolizumab for Patients with Moderately to Severely Active Ulcerative Colitis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Vedolizumab
    Bulgaria Czechia Hungary Latvia Poland Romania +1

  • Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

    Not recruiting

    3 1
    Investigated Drugs:
    • Astegolimab
    Austria Belgium Bulgaria Czechia Denmark France +10

  • Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Cardiovascular disorder
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Clopidogrel
    • Milvexian
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Clopidogrel
    • Milvexian
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Atrial fibrillation
    Investigated Drugs:
    • Andexanet Alfa
    • Apixaban
    • Milvexian
    Belgium Bulgaria Croatia Czechia Denmark Estonia +13

  • Study of Olaparib and Pembrolizumab for Patients with Advanced Cancer with HRRm or HRD Mutations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Olaparib
    • Pembrolizumab
    France Germany Italy Latvia Poland Romania +2

  • Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Inclisiran
    Austria Belgium Bulgaria Croatia Czechia Denmark +14
Previous Page
1 … 11 12 13 14 15
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!